What was the reported price per share for the Cardiff Oncology (CRDF) option grant?

The stock option grant to Interim CEO Mani Mohindru was reported at a price of $0.0000 per option. This indicates the award was granted at no cash cost to the reporting person as part of her compensation structure.

Cardiff Oncology grants 200,000 stock options to CEO

Mohindru Mani reported acquisition or exercise transactions in this Form 4 filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Mohindru Mani reported acquisition or exercise transactions in this Form 4 filing.

Cardiff Oncology, Inc. reported that Interim CEO and director Mani Mohindru received a grant of stock options. The award covers 200,000 stock options, recorded at a price of $0.0000 per option, and increases her directly held option position to 368,766 options following the transaction.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Mohindru Mani

Role Interim CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	200,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 368,766 contracts (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cardiff Oncology (CRDF) report for Mani Mohindru?

Cardiff Oncology reported that Interim CEO and director Mani Mohindru received a grant of 200,000 stock options. This equity award was recorded at a price of $0.0000 per option and classified as a grant, award, or other acquisition.

How many Cardiff Oncology (CRDF) stock options were granted in this Form 4?

The Form 4 shows a grant of 200,000 stock options to Interim CEO Mani Mohindru. After this grant, her directly held option position is reported as 368,766 stock options in total, according to the ownership figures in the filing.

What type of transaction is shown in the Cardiff Oncology (CRDF) Form 4?

The transaction is classified as an acquisition of derivative securities through a grant or award. It involves stock options rather than common shares and is coded as a grant, award, or other acquisition in the Form 4 details.

What is Mani Mohindru’s role at Cardiff Oncology (CRDF) in this Form 4?

The Form 4 identifies Mani Mohindru as both a director and an officer of Cardiff Oncology, serving as Interim CEO. The reported stock option grant reflects equity compensation tied to her leadership and board responsibilities at the company.

How did the Cardiff Oncology (CRDF) option grant affect reported holdings?

Following the grant of 200,000 stock options, Mani Mohindru’s directly held option holdings increased to 368,766. This figure represents her total reported derivative holdings after the transaction, as disclosed in the Form 4 ownership table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/18/2026 - 04:01 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mohindru Mani

(Last)

(First)

(Middle)

11055 FLINTKOTE AVENUE

C/O CARDIFF ONCOLOGY, INC.

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Interim CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options	$1.56	02/17/2026		A		200,000		05/17/2026	02/17/2036	Common Stock	200,000	$0	368,766	D

Explanation of Responses:

	/s/ Mani Mohindru	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR